Carnegie Mellon University Technology Transfer Office
This article was originally published in Start Up
Executive SummaryThe same model CMU has used successfully in high technology (it incubated the search engine company, Lycos Inc.) can be applied to biomedical start-ups. But because development timeframes are much longer, meaning that more resources must usually be applied to maximize the probability of success, CMU doesn't expect to form that many biomedical enterprises.
You may also be interested in...
A series of basic research insights around the cell death process called ferroptosis could form the underpinnings of a new class of treatments aimed at drug resistant tumors.
Recent clinical data using antisense drugs in neurological diseases are encouraging signs that targeting genetic drivers of ALS with antisense oligonucleotides or other gene-altering drugs could halt progression of several forms of the disease.
No NASH treatments are on the market yet, but Phase III data readouts are emerging, mid-stage drugs are demonstrating their capabilities and combinations are in view.